Olayemi Osiyemi, MD
Infectious Disease · West Palm Beach, FLNPI 1063522332
Payments from drug & device makers
Across 2,670 payments — averaging $3296.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.9M
- Regeneron$2.6M
- Viiv Healthcare Company$1.4M
- Gilead$1.1M
- AbbVie$603K
- Pharmacyclics LLC, An Abbvie Company$158K
- plus $120K from 23 others
Across 36 payments — averaging $4370.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$119K
- Eli Lilly$36K
- Gilead$2K
What the payments were for
- Consulting fees$41,42017%
- Speaking & faculty fees$145,77559%
- Travel & lodging$29,67612%
- Food & beverage$30,50312%
- Education$3310%
- Gifts$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 374 | $2,902,309 |
| Regeneron | 89 | $2,573,117 |
| Viiv Healthcare Company | 672 | $1,392,744 |
| Gilead | 745 | $1,050,495 |
| AbbVie(2 entities) | 147 | $603,349 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $158,307 |
| GSK | 27 | $65,041 |
| Janssen Research & Development, LLC | 8 | $27,917 |
| Theratechnologies Inc. | 54 | $13,090 |
| Janssen Scientific Affairs, LLC | 4 | $3,069 |
| Johnson & Johnson(2 entities) | 237 | $2,995 |
| Sanofi Pasteur Inc. | 1 | $2,350 |
| Insmed, Inc. | 94 | $1,898 |
| Melinta Therapeutics, LLC | 82 | $1,169 |
| Paratek Pharmaceuticals, Inc. | 32 | $664 |
| Shionogi Inc | 37 | $591 |
| Janssen Products, LP | 4 | $387 |
| Vyera Pharmaceuticals, LLC | 12 | $224 |
| Tetraphase Pharmaceuticals, Inc. | 21 | $176 |
| La Jolla Pharmaceutical Company | 7 | $143 |
| EMD Serono, Inc. | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Mylan Specialty L.p. | 1 | $50 |
| Nabriva Therapeutics, PLC | 3 | $46 |
| Mylan Pharmaceuticals Inc. | 2 | $43 |
| Galderma Laboratories, L.p. | 2 | $37 |
| Mayne Pharma Commercial LLC | 2 | $31 |
| Organogenesis Inc. | 1 | $26 |
| Smith+Nephew | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,800,424 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 315 | $1,222,633 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 121 | $434,651 |
| DovatoDolutegravir Sodium/Lamivudine | 132 | $423,401 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 95 | $409,300 |
| TivicayDolutegravir Sodium | 136 | $357,200 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 99 | $338,221 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 87 | $332,931 |
| DescovyEmtricitabine/Tenofov Alafenam | 103 | $228,739 |
| CabenuvaCabotegravir/Rilpivirine | 29 | $196,199 |
| JulucaDolutegravir/Rilpivirine | 32 | $123,375 |
| PrezcobixDarunavir/Cobicistat | 14 | $38,388 |
| IsentressRaltegravir Potassium | 13 | $25,355 |
| Daptomycin | 43 | $20,934 |
| ErtapenemErtapenem Sodium | 25 | $15,442 |
| MounjaroTirzepatide | 14 | $14,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,050,495 | $1,784,303505 claims |
| Viiv Healthcare CompanyTriumeq, Dovato, Tivicay, Cabenuva, Juluca | $1,392,744 | $1,534,825450 claims |
| Janssen Products, LPSymtuza | $387 | $409,30095 claims |
| Johnson & JohnsonPrezcobix | $2,995 | $38,38814 claims |
| MerckIsentress | $2,902,309 | $25,35513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in West Palm Beach
- Moti RamgopalFort Pierce$13.5M
- Larry BushAtlantis$9.3M
- Charlotte-Paige RolleOrlando$6M
- Edwin DejesusOrlando$5.9M
- Dushyantha JayaweeraMiami$5.1M
- Federico HinestrosaOrlando$5.1M
- Godson OguchiOrange City$5M
- Ammara MushtaqGainesville$2.7M
- Efrain GarciaMiami$2.5M
- Kami KimTampa$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.